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Abstract
Objective: Correct inhaler technique is central to effective delivery of asthma therapy. The study
aim was to identify factors associated with serious inhaler technique errors and their prevalence
among primary care patients with asthma using the Diskus dry powder inhaler (DPI). Methods:
This was a historical, multinational, cross-sectional study (2011–2013) using the iHARP
database, an international initiative that includes patient- and healthcare provider-reported
questionnaires from eight countries. Patients with asthma were observed for serious inhaler
errors by trained healthcare providers as predefined by the iHARP steering committee.
Multivariable logistic regression, stepwise reduced, was used to identify clinical characteristics
and asthma-related outcomes associated with 1 serious errors. Results: Of 3681 patients with
asthma, 623 (17%) were using a Diskus (mean [SD] age, 51 [14]; 61% women). A total of 341
(55%) patients made 1 serious errors. The most common errors were the failure to exhale
before inhalation, insufficient breath-hold at the end of inhalation, and inhalation that was not
forceful from the start. Factors significantly associated with 1 serious errors included asthma-
related hospitalization the previous year (odds ratio [OR] 2.07; 95% confidence interval [CI],
1.26–3.40); obesity (OR 1.75; 1.17–2.63); poor asthma control the previous 4 weeks (OR 1.57;
1.04–2.36); female sex (OR 1.51; 1.08–2.10); and no inhaler technique review during the previous
year (OR 1.45; 1.04–2.02). Conclusions: Patients with evidence of poor asthma control should be
targeted for a review of their inhaler technique even when using a device thought to have a
low error rate.
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Introduction
The prevalence of uncontrolled asthma has remained at
approximately 50% in recent European surveys despite the
availability of effective therapies [1–3], with patient errors in
using their inhaler devices likely playing a role [3,4]. Proper
inhaler technique is an important component of effective
asthma therapy: bronchodilators and inhaled corticosteroids
(ICS) are delivered via a variety of inhaler devices, each with
its specific dose preparation and handling technique, advan-
tages and disadvantages [4–7].
Correspondence: David B. Price, Academic Primary Care, University of
Aberdeen, Polwarth Building, Foresterhill, Aberdeen, United Kingdom
AB25 2ZD. Tel: +44 160 387 1500. E-mail: dprice@rirl.org
 The Author(s). This is an Open Access article distributed under the
terms of the Creative Commons Attribution-NonCommercial-
NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/
4.0/), which permits non-commercial re-use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited, and is
not altered, transformed, or built upon in any way.
Data derived from randomized controlled trials (RCTs)
indicate that clinical outcomes do not differ significantly
among inhaler devices; however, these studies typically
include only highly trained patients with correct inhalation
technique [6–9]. Indeed, meta-analyses of observational
studies and RCTs report that any inhaler device type is
similarly effective as long as the patient is able to use it
correctly and there is drug remaining in the device [7,10].
However, findings from observational studies indicate that
patients with obstructive lung disease commonly misuse
inhalers in clinical practice [11–16], and poor inhaler
technique is associated with worse clinical outcomes [16–20].
The correct use of an inhaler involves device-specific dose
preparation steps followed by the inhalation pattern appro-
priate to the device. The ideal pattern with a dry powder
inhaler (DPI) is a full exhalation (ideally to residual volume),
then a rapid and forcible inhalation (also described as ‘‘deep
and hard as you can’’), followed by a breath-hold for 10 s or as
long as possible [5]. Unlike standard pressurized metered-
dose inhalers (pMDIs), DPIs are breath-actuated so they
obviate the need to co-ordinate actuation and inhalation [5]. It
has been suggested that some patients experiencing an asthma
exacerbation could be unable to generate the forcible
inhalation required with DPIs [21]. However, the Diskus
DPI (also known as the Accuhaler) is designed to facilitate
ease of use, and there is some evidence to suggest that, of the
DPIs, this device is associated with fewest inhaler technique
errors [14,22–24]. In a randomized study of patients with
obstructive lung disease who were hospitalized for an
exacerbation, the highest number of optimum inhalation
profiles were observed with the Diskus (100%), followed by a
pMDI with a Volumatic spacer (87%), and the lowest number
with MDIs alone (14%) [24].
The global Helping Asthma in Real People (HARP)
project seeks to understand and address the reasons for
uncontrolled asthma [25]. The HARP inhaler technique
assessment initiative (iHARP) is an extension of HARP that
incorporates an assessment of potential handling errors and an
appraisal of patient inhalation profile against device-specific
thresholds in addition to the standard review [26,27]. Inhaler
use has been reviewed for 5000 patients since the launch of
iHARP in June 2011. The aim of this study was to use iHARP
data to identify factors associated with serious inhaler
technique errors, as observed by healthcare providers
(HCPs), and their prevalence among primary care patients
with asthma using the Diskus dry powder inhaler.
Methods
Data source
This cross-sectional observational study used anonymized
patient data from the iHARP database, an international
database administered by the Respiratory Effectiveness Group
[28] comprising anonymized data from practices receiving the
iHARP asthma review service [26,27]. Data for the study
were collected from June 2011 to November 2013; permission
to use the data for research was obtained from primary care
practices in Australia and seven European countries (the
United Kingdom [UK], Italy, Spain, the Netherlands, France,
Norway and Sweden). The data included patient demographic
characteristics, respiratory reviews by trained HCPs and
results of asthma questionnaires completed by patients on the
day of the iHARP asthma review. For patients assessed within
the UK, these data were linked to anonymized clinical,
diagnostic and prescribing information from electronic med-
ical records.
Each of the participating centers obtained appropriate
ethics approval for the iHARP asthma review service based
on their country-specific requirements. This study was
registered with the European Network of Centers for
Pharmacoepidemiology and Pharmacovigilance (as
ENCePP/SDPP/8020) [29].
Cohort definition
The cohort drawn from the iHARP database for the current
study was restricted to adult patients (18 years old) who
were receiving fixed-dose combination ICS/LABA therapy
delivered by a Diskus device.
Patients eligible for iHARP respiratory review, an ongoing
international initiative, are 16 years and older, have a current
diagnosis of asthma and have received two or more prescrip-
tions for fixed-dose combination ICS/long-acting beta-agonist
(LABA) therapy in the year before the review [26,27].
Patients are excluded from iHARP if they have a diagnosis of
chronic obstructive pulmonary disease (COPD) or any
chronic respiratory disease other than asthma, or if they are
prescribed separate ICS in addition to fixed-dose combination
ICS/LABA, are receiving long-term systemic treatment for
asthma (e.g. maintenance oral corticosteroids, theophylline,
leukotriene receptor antagonists or anti-IgE therapy), or had
received oral corticosteroids and/or antibiotics for a lower
respiratory condition in the 2 weeks before respiratory review.
Study data and definitions
Demographic and clinical characteristics were obtained from
the iHARP database (see Supplementary material for further
details). All patients were asked whether their inhaler
technique had been reviewed in the previous year by an
HCP, and patients were asked to self-assess their inhaler
technique using a Likert scale with scores ranging from 1 (‘‘I
think my inhaler technique is very poor’’) to 6 (‘‘I think my
inhaler technique is excellent’’).
Self-reported adherence to asthma therapy was assessed
for patients from the UK, Italy, Spain, Australia, Sweden,
France and Norway using the Medication Adherence
Rating Scale (MARS) [30]. Adherence to asthma therapy
for patients from the Netherlands was assessed using
patients’ answers to the question, ‘‘Do you ever forget
your prevention inhalation medication?’’ Adherence was
categorized as (1) poor for responses of ‘‘very often’’ or
‘‘always’’; (2) borderline for responses of ‘‘now and then’’
or ‘‘regularly’’ and (3) good for responses of ‘‘never’’ and
‘‘rarely.’’
The Global INitiative for Asthma (GINA) criteria [31]
were used to assess asthma control during 1 week preceding
the clinic visit; and the Asthma Therapy Assessment
Questionnaire (ATAQ) [32] was used to assess asthma control
during the preceding 4 weeks (see Supplementary material for
details).
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The numbers of patient-reported acute courses of oral
corticosteroids, asthma-related hospitalizations and severe
asthma exacerbations in the prior year were recorded during
the iHARP review on the patient-completed questionnaire.
Severe exacerbations were defined as patients having had
either an asthma-related hospitalization or a course of oral
corticosteroids (as defined above) in the prior year.
Study endpoint: serious inhaler technique errors
Serious inhaler technique errors identified by the HCPs were
defined as errors potentially limiting drug uptake to the lungs,
as enumerated by the iHARP steering committee before
commencing the study. Table 1 depicts the checklist of pre-
defined serious errors for the Diskus device.
The study HCPs – physicians in Italy, Norway and Spain,
pharmacists in Australia, and nurses in the UK, the
Netherlands, Sweden and France – were trained and tested
to identify serious inhaler errors by watching a standardized
instructional video. Eligible patients were invited to respira-
tory reviews at their primary care practices, during which the
HCPs observed patients using their inhaler once, or twice if a
second dose were required, and recorded serious errors
against the checklist (Table 1).
Statistical analyses
Analyses were performed with SPSS Statistics versions 19
and 21 (IBM SPSS Statistics, Feltham, Middlesex, UK), SAS
version 9.3 (SAS Institute, Marlow, Buckinghamshire, UK)
and Microsoft Excel 2007 (Microsoft Corporation, Redmond,
Washington). Statistically significant results were defined as a
p value of 0.05.
Characteristics of patients who made no serious errors
using a Diskus device were compared with those of patients
making one or more (1) serious errors. Variables measured
on the interval or ratio scale were compared using Student’s t-
test for normally distributed data and the Mann–Whitney U-
test for skewed data. Categorical variables were compared
using the 2 test.
Univariable logistic regression models, with a dichotom-
ous indicator variable for serious errors made (yes/no) as the
dependent variable and each patient characteristic as an
explanatory (or predictor) variable, were first used to identify
characteristics associated with making serious errors.
Demographic and clinical characteristics associated with
making 1 serious errors in the univariable model (p5 0.05)
were then entered into a multivariable model, which was
stepwise reduced to produce a final list of non-collinear
independently associated variables. Significant interactions
were defined as p value 50.10. A list of demographic and
clinical characteristics included in the univariable model is in
the Supplementary material.
Results
Patients
There were 3681 patients with asthma in the iHARP database
who had a respiratory review between June 2011 and
November 2013. Of these patients, 627 (17%) were using a
Diskus inhaler. After excluding four (0.5%) patients aged518
years, the final study cohort included 623 adult patients with
asthma using Diskus who were from the UK (232 [37%]),
Italy (149 [24%]), Spain (102 [16%]), the Netherlands (83
[13%]), Australia (37 [6%]), France (8 [1%]), Norway (5
[1%]) and Sweden (7 [1%]). The final study cohort comprised
61% women and had a mean (SD) age of 51 (14) years
(Table 2). Approximately three quarters of patients had
recorded lung function results; of these, 69% had a percent
predicted forced expiratory volume in 1 s (FEV1) or peak
expiratory flow (PEF) that was 480% (Supplemental
Table S1).
Serious errors and characteristics of patients making
serious errors
Fifty-five percentage of patients made from 1 to 10 serious
errors, most commonly one (157 [25%]), two (92 [15%]) or
three errors (55 [9%]); 37 patients (6%) made four or more
errors. The most frequent errors were the failure to exhale
before inhalation, insufficient (or absent) breath-hold at the
end of inhalation and inhalation that was not forceful from the
start (Figure 1).
Patients making 1 serious errors were significantly more
likely to be female, obese or lacking a university degree than
those making no error (Table 2). Age, smoking status, the
duration of asthma, the prevalence and severity of rhinitis and
lung function test results were not significantly different
between patients making 0 and 1 serious errors (Table 2,
Supplemental Table S1). Patient-reported adherence to ther-
apy did not differ between patients making 0 and 1 serious
errors (Table 3).
Patients making 1 serious errors were significantly less
likely to report that they had their inhaler technique reviewed
by an HCP in the prior year or to report good to excellent
inhaler technique proficiency (Table 3). In addition, those
making 1 serious errors were significantly more likely to
have poor asthma control in the previous 1–4 weeks, as
assessed using the GINA criteria and/or ATAQ score (Table 3
and Supplemental Table S1).
Severe exacerbations and asthma-related hospitalizations
during the previous year were significantly more frequent
among patients making 1 serious inhaler errors than among
those making no errors. The number of acute courses of oral
corticosteroids was not significantly different between these
Table 1. Checklist of predefined serious errors for the Diskus device.
Does not slide cover as far as possible
Does not slide lever fully to open mouthpiece
Holds in a downward position after dose preparation
(before an inhalation)
Shakes after dose preparation
Blowing into the device
Failure to exhale before inhalation
Failure to put in mouth and seal lips around mouthpiece
Failure to inhale through mouthpiece
Inhalation through the nose
Inhalation is not forceful from the start
No breath-hold for at least 3 s
Does not prepare second dose correctly
Does not correctly inhale second dose as above
Does not know when his or her device is empty
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two patient groups overall (Table 3) or as a dichotomized
variable (0 versus 1 oral corticosteroid course: p¼ 0.070 for
the comparison between patients making 0 versus 1 serious
error).
Risk factors for making serious inhaler technique
errors: multivariable model
The univariable logistic regression results for the risk of a
serious error are reported in the online Supplementary
material (Supplemental Tables S2–S4).
In the multivariable logistic regression analysis, the most
significant association with making 1 serious error was
having experienced 1 asthma-related hospitalizations (inpa-
tient or emergency department attendance) in the previous
year (Table 4). Other factors significantly associated with
making 1 serious errors included being female, being obese
(versus underweight/normal weight), having no inhaler tech-
nique review in the prior year, and having poor asthma control
in the prior 4 weeks (via ATAQ) versus having good/partial
control.
There was a significant interaction between body mass
index (BMI) and inhaler technique review. Among over-
weight patients, those who had no inhaler technique review in
the previous year were more likely to make a serious error
compared with patients who had their inhaler technique
Table 2. Patient characteristics grouped by frequency of serious inhaler technique error (0 versus 1).
Characteristic Total N (%) (n¼ 623) 0 errors (n¼ 282) 1 errors (n¼ 341) p value
Age, mean (SD) 51 (14) 50 (15) 51 (14) 0.84a
18–30 years, n (%) 66 (11) 36 (13) 30 (9)
31–50 years, n (%) 219 (35) 94 (33) 125 (37)
51–70 years, n (%) 313 (50) 140 (50) 173 (51)
470 years, n (%) 25 (4) 12 (4) 13 (4)
Sex, female, n (%) 380 (61) 159 (56) 221 (65) 0.032b
male 243 (39) 123 (44) 120 (35)
Body mass indexc, n (%)
Underweight 8 (1) 4 (1) 4 (1) 0.036b
Normal 214 (34) 107 (38) 107 (31)
Overweight 212 (34) 102 (36) 110 (32)
Obese 189 (30) 69 (25) 120 (35)
Smoking status, n (%)
Current smoker 78 (13) 28 (10) 50 (15) 0.179b
Ex-smoker 189 (30) 91 (32) 98 (29)
Non-smoker 356 (57) 163 (58) 193 (57)
Educationd, known status, n (%) (n¼ 499 [80]) (n¼ 216) (n¼ 283)
PG or professional degree 11 (2) 4 (2) 7 (3) 0.006b
University degreee 157 (31) 80 (37) 77 (27)
Secondary educatione 207 (41) 88 (41) 119 (42)
Primary educatione 100 (20) 39 (18) 61 (22)
None 24 (5) 5 (2) 19 (7)
Percentages are column percentages. BMI, body mass index; PG, postgraduate; SD, standard deviation.
aMann–Whitney U test.
b2 test.
cUnderweight BMI518.5 kg/m2; normal BMI¼ 18.5–24.99 kg/m2; overweight BMI¼ 25–29.99 kg/m2; obese BMI 30 kg/m2.
dErrors by education reported as n (%) of known status.
eCompleted or some education.
Figure 1. Percentage of patients making each type of serious inhaler error with the Diskus.
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reviewed (Table 5). Among patients who had no inhaler
technique review in the previous year, overweight and obese
patients were more likely to make a serious error compared
with underweight/normal weight patients. (The proportions of
patients reporting a previous inhaler technique review were
41% of those underweight/normal weight, 52% of those
overweight and 50% of those obese; 2 test p¼ 0.059).
Discussion
We found that errors in Diskus inhaler technique are common
among patients with asthma, with over half of patients in this
study making 1 serious errors. The incidence of serious
errors was significantly higher among female patients, obese
patients and those who had not had their inhaler technique
reviewed within the previous year, who were of lower
educational level and who assessed their own technique as
poor. We found that asthma-related hospitalizations and
severe exacerbations during the previous year, and poor
asthma control during the previous 4 weeks as measured on
the ATAQ, were more common among patients who made 1
serious errors. In the multivariable model, risk factors
identified for making 1 serious errors were having
Table 3. Clinical characteristics grouped by serious inhaler error category (0 versus 1).
Clinical characteristic Total N (%) (n¼ 623) 0 error (–¼ 282) 1 errors (n¼ 341) p value
Patient-reported prior inhaler review by HCPb, n (%) 297 (48) 150 (53) 147 (43) 0.012
Patient self-assessment of inhaler technique, n (%), known (n¼ 588 [94]) 270 (96) 318 (93)
Very poor to poor 24 (4) 11 (4) 13 (4) 0.024
Fair to average 122 (21) 43 (16) 79 (25)
Good to excellent 442 (75) 216 (80) 226 (71)
ATAQ asthma control, n (%), known (n¼ 622 [100]) 282 (100) 340 (99.7)
Poor control 137 (22) 47 (17) 90 (27) 0.012
Partial control 469 (75) 228 (81) 241 (71)
Good control 16 (3) 7 (3) 9 (3)
Adherence to therapyc, n (%)
Poor 202 (37) 84 (34) 118 (40) 0.087
Borderline 18 (3) 5 (2) 13 (4)
Good 320 (59) 156 (64) 164 (56)
Adherence to therapy in the Netherlandsd, n (%), known (n¼ 59 [71]) 26 (70.3) 33 (72)
Poor 2 (3) 2 (7.7) 0 (0) 0.12
Borderline 0 0 (0) 0 (0)
Good 57 (97) 24 (92.3) 33 (100)
Acute courses of oral corticosteroidsb, n (%)
0 380 (61) 183 (65) 197 (58) 0.13
1 139 (22) 58 (21) 81 (24)
2 59 (10 27 (10) 32 (9)
3 45 (7) 14 (5) 31 (9)
Severe exacerbationsb,e, n (%), known (n¼ 622 [100]) 282 (100) 340 (99.7)
0 355 (57) 176 (62) 179 (53) 0.044
1 132 (21) 55 (20) 77 (23)
2 135 (22) 51 (18) 84 (25)
Hospitalizationsb, n (%)
0 531 (85) 255 (90) 276 (81) 0.008
1 42 (7) 10 (4) 32 (9)
2 21 (3) 8 (3) 13 (4)
3 28 (5) 9 (3) 19 (6)
Abbreviations: ATAQ, Asthma Therapy Assessment Questionnaire; FEV1, forced expiratory volume in 1 second; HCP, health care practitioner; PEF,
peak expiratory flow.
a2 test.
bIn the year before an iHARP respiratory consultation.
cNumber (%) calculated as percentage of patients from the UK, Italy, Spain, Australia, Sweden, France and Norway (n¼ 245 for 0 serious errors and
n¼ 295 for 1 serious error).
dNumber (%) calculated as percentage of known patients from the Netherlands (n¼ 37 for 0 serious errors and n¼ 46 for 1 serious error).
eNumber (%) calculated as percentage of known.
Table 4. Demographic and clinical factors associated with making 1 serious error versus 0 (multivariable results).
Reference category Category Odds ratio (95% CI) p value Overall p value
Sex Male Female 1.51 (1.08–2.10) 0.017
BMI Underweight/Normal weight Overweight 1.18 (0.80–1.74) 0.401 0.024
Obese 1.75 (1.17–2.63) 0.007
Inhaler review Yes No 1.45 (1.04–2.02) 0.027
ATAQ Good control/Partial control Poor control 1.57 (1.04–2.36) 0.031
Inpatient admission
or ED attendance
0 1 2.07 (1.26–3.40) 0.004
Abbreviations: ATAQ, Asthma Therapy Assessment Questionnaire; BMI, body mass index; ED, emergency department.
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experienced 1 asthma-related hospitalizations during the
previous year, being obese, being female, having poor asthma
control during the previous 4 weeks (as measured by the
ATAQ), and no patient-reported review of inhaler technique
by an HCP during the previous year.
Results of this study support the consensus that incorrect
inhaler technique is a common issue rather than an exception
among patients with asthma [4,8,9]. The two errors most
frequently reported in our study (failure to exhale before
inhalation and insufficient [or absent] breath-hold at the end
of inhalation) are in agreement with previously published
reports of the most frequently observed errors with the Diskus
being ‘‘no exhalation before inhalation’’ and ‘‘no breath-
holding after inhalation’’ [13,15,23,33]. The third most
common error in our study (inhalation that was not forceful
from the start) has also been reported [13,15,33,34]. Specific
dose preparation errors with the Diskus (does not slide cover
as far as possible and does not slide lever fully to open
mouthpiece) were found to be low (4.3% total), consistent
with previous reports in which 7.3% of patients incorrectly
loaded the dose [16] and 2.5% did not slide the lever as far as
possible [23]. Other errors reported as common with the
Diskus in previous observational studies include incorrect
dose metering [15], failure to prime the device correctly
[33,34] and exhaling into the device [13,23].
Our findings suggest that some patient characteristics may
potentially predict incorrect inhalation technique, specifically
female sex and obesity. One alternative explanation for these
findings could be that suboptimally controlled asthma is more
common in obese patients [35], and the phenotype of obese
non-eosinophilic asthma responds poorly to ICS [36,37].
Moreover, we cannot rule out the possibility of these being
statistically significant findings that are of no clinical
significance or relevance.
We found that patients with a lower level of education, as
previously reported [13,16,38], were more likely to make a
serious error, although education was not included in the
multivariable model because it was confounded by the BMI
and inhaler review status. An association between inhaler
misuse and older age has been described previously
[13,16,38,39]. We found no significant association with age,
although only 4% of patients in the study were older than 70
years. The incidence of errors was also not significantly
associated with lung function in this study, perhaps because of
our broad study population that was not limited to patients
with severe asthma [21,38]. Instead, we found that sex and
BMI may be more important factors to consider when
selecting inhaler device.
The association between incorrect inhaler technique and
lack of prior inhaler technique instruction by HCPs has been
described previously [13,16,33,38]. However, in practice it is
relevant not only whether inhaler technique instruction is
given but also the nature of that instruction, as not all methods
of instruction are equally effective. Furthermore, the action of
checking to see what the patient is actually doing incorrectly
and the associated feedback/correction from the HCP may be
critical and needs to be considered [40]. Inhaler training has
been shown to significantly improve the proportion of patients
with proper inhaler technique and to produce improved
asthma control scores [17,41–43]. That said, many HCPs are
not skilled in using inhalation devices and could also benefit
from training [44]; consequently, patients may not receive
appropriate (if any) inhaler instruction.
We also found that a patient self-assessment of inhaler
technique as being poor was associated with increased
likelihood of inhaler errors, suggesting that a simple query
to patients could be an easy, fast and inexpensive screening
method to identify patients who would benefit from inhaler
training. These data are actually inconsistent with other
research showing that individuals who demonstrate errors
may think they are using their devices correctly [9,45]. While
it is easy to address inhaler technique for those who feel there
is a problem, being able to identify those who have incorrect
technique but do not realize it is more challenging. We need
to look at other factors to detect those individuals, and the
findings of this study have identified some of those factors.
Strengths of this study are its observational design and the
inclusion of data from more than 600 patients undergoing
inhaler technique review in a routine clinical setting in eight
different countries. We intentionally applied minimal exclu-
sion criteria in order to study a heterogeneous, representative
population of patients with asthma to maximize generaliz-
ability of results to primary care practice; this was in contrast
to enrolment in RCTs, which typically include only patients
who demonstrate ideal inhaler technique in order to minimize
potential bias. In addition, this study included patient-
reported feedback, providing important insight into patient
perspectives.
The use of real-life datasets presents a set of limitations for
which adjustments are not always possible, particularly the
Table 5. Odds ratios of recording a serious error (vs. not) for categorical variables – multivariable analyses (including interaction).
Reference category Category Odds ratio (95% CI) p value
Sex Male Female 1.50 (1.07, 2.11) 0.018
BMI by Inhaler check Inhaler check¼YES Underweight/Normal weight Overweight 0.75 (0.43, 1.32) 0.090
Obese 1.26 (0.70, 2.27)
Inhaler check¼NO Overweight 1.77 (1.03, 3.03)
Obese 2.26 (1.28, 3.99)
Inhaler check by BMI Underweight/Normal Inhaler check¼Yes No 0.91 (0.53, 1.57) 0.090
Overweight No 2.14 (1.22, 3.76)
Obese No 1.63 (0.88, 3.01)
ATAQ Good control/Partial control Poor control 1.60 (1.06, 2.41) 0.026
Inpatient admission
or ED attendance
0 1+ 2.00 (1.22, 3.29) 0.006
Abbreviations: ATAQ, Asthma Therapy Assessment Questionnaire; BMI, body mass index; ED, emergency department.
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issue of missing data, which in the required anonymized form
was not feasible to retrieve. As the missing data in our study
appeared randomly distributed (data not shown), we believe
this limitation is unlikely to substantially bias the results.
Another potential confounder is the possibility of inter-
individual observation bias among the iHARP HCPs. While
iHARP nurses and doctors receive the same training for
observing and evaluating inhaler technique, different inter-
pretations of observed technique are still possible, particularly
with regard to the more subjective errors such as inhalation
being ‘‘not forceful’’. Subsequent studies would benefit from
incorporating objective appraisals of patient inhalation pro-
files using specific thresholds with devices such as the In-
Check DIAL (Alliance Tech Medical, Granbury, TX), the
Aerosol Inhalation Monitor (Vitalograph), or any other
system that measures inhalation profile [46]. Furthermore,
medical staff were not blinded to the questionnaire results,
which could potentially have influenced their observations.
Data such as frequency of hospitalizations and exacerbations
in the year preceding the patient review were obtained via a
patient-completed questionnaire; hence, recall bias may be a
further limitation of the study. Finally, the design of this study
does not enable us to address the issue of cause and effect.
Using an international dataset enabled us to compare
patient inhaler technique in several countries and to
identify incorrect technique as a widespread problem.
However, a limitation of this approach is possible
confounding caused by inter-country differences in how
disease outcomes are measured and recorded (e.g. the
Netherlands does not use the MARS to measure
adherence).
Nonetheless, although observational studies such as
this may lack the internal validity achievable in RCTs,
they provide a valuable insight into patient behavior
and health outcomes in clinical practice. As such our
findings should be considered in conjunction with those
arising from other study designs including RCTs.
Our study focused on a single dry powder device,
the Diskus inhaler, with which a rather low rate of
errors has previously been reported [14,22–24].
Additional areas for further investigation include the
characteristics of patients who made more than one
serious error (quantity) and the impact of error type
(quality) in order to clarify the importance and clinical
relevance of each type of error. Further study is also
needed to identify factors associated with making
serious errors with other devices. The importance of
choosing the right inhaler device for the individual
patient is widely recognized [8,9,47,48], and selecting
devices based on patient characteristics and preferences
could be an important step for improving asthma
control and along with assessing adherence should be
the first step before increasing therapy. Patient prefer-
ence for an inhaler device combined with ease of
inhaler instructions is associated with an increased
likelihood of correct use [14,34]. Personalized prescrib-
ing of inhaler devices could provide a safe and
effective method of achieving better asthma control,
fewer exacerbations, fewer hospital admissions and
ultimately lower healthcare costs.
Conclusions
We found that inhaler technique errors are common among
patients with asthma using the Diskus inhaler. The most
frequent error in this study, the failure to exhale before
inhalation, was observed in one third of patients. We found
that errors were more common among female patients and
obese patients. In addition to these two patient characteristics,
factors significantly associated with making 1 serious errors
were an asthma-related hospitalization or emergency depart-
ment attendance the prior year, lack of an inhaler technique
review within 1 year and poor asthma control over the
previous 4 weeks. These findings highlight the importance of
regular monitoring of inhaler technique and can aid in
identifying patients who could benefit from a review of their
Diskus inhaler technique. Patients with evidence of poor
asthma control should be targeted for a review of their inhaler
technique even when using a device thought to have a low
error rate.
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